Opportunity Scan

Diamonds in the Rough

Cross-referencing fundamental value against technical exhaustion to isolate beaten-down ARKG constituents that screen cheap and oversold. The bottom-right quadrant — high earnings yield, low RSI — is the prime hunting ground, especially where money flow (MFI) shows quiet accumulation despite the falling price.

10 in diamond zone29 scored

Educational screen, not investment advice. “Diamond” classification is a mechanical valuation-vs-RSI split around the cohort median earnings yield and an RSI of 50.

Alpha Quadrant — Valuation × Technical Exhaustion

X = earnings yield (cheaper right) · Y = RSI 14 (more oversold lower) · bubble = market cap · color = money flow.

Accumulation (MFI ≥ 55)Neutral flowDistribution (MFI ≤ 45)Diamond-zone ring

◆ Diamond in the RoughCheap + oversold. Deep value in a technically exhausted state — the prime target.

Fairly Valued WinnerCheap + extended. Strong action backed by earnings, but late for new entries.

Value TrapExpensive + beaten down. Falling yet still richly valued — structurally suspect.

Momentum DarlingExpensive + extended. Crowded leaders with mean-reversion risk.

Diamond Candidates

Ranked by a composite of earnings yield, ROIC, oversold RSI, recent weakness, and improving money flow.

#
1	NRIX	Nurix Therapeutics, Inc. Common stock	67.9	29.83%	0.29	27	-34.60%	35	safe
2	VCYT	Veracyte, Inc.	60.6	5.64%	0.24	28	-43.89%	41	safe
3	ILMN	Illumina Inc	48.8	3.02%	0.37	35	-22.54%	44	safe
4	TWST	Twist Bioscience Corporation Common Stock	33.4	-1.99%	-0.46	38	-19.18%	58	safe
5	CRSP	CRISPR Therapeutics AG	30.0	-11.85%	-0.24	32	-15.52%	33	safe
6	NTRA	Natera, Inc. Common Stock	30.0	-0.58%	-0.18	34	-18.16%	31	safe
7	IONS	Ionis Pharmaceuticals, Inc. Common Stock	30.0	-9.63%	-0.27	24	-33.32%	22	distress
8	LLY	Eli Lilly & Co.	29.7	2.62%	0.69	70	+16.88%	64	safe
9	FRNM	Freenome, Inc. Common stock	29.4	--	--	36	-13.82%	33	--
10	WGS	GeneDx Holdings Corp. Class A Common Stock	29.1	-6.15%	-0.36	36	-23.55%	43	distress
11	NTLA	Intellia Therapeutics, Inc	28.6	-33.96%	-0.99	36	-14.39%	43	distress
12	ARCT	Arcturus Therapeutics Holdings Inc. Common Stock	28.0	-169.17%	-0.57	37	-24.00%	35	distress
13	IAM	Iambic Therapeutics, Inc. Common Stock	27.0	--	--	41	-18.89%	51	--
14	CMPS	COMPASS Pathways Plc American Depository Shares	26.8	-22.36%	-1.22	38	-19.91%	30	distress
15	CERS	Cerus Corp	26.2	-0.55%	-0.03	39	-10.99%	40	distress

Short-Squeeze Watch

Constituents with the highest composite squeeze score — heavy short interest meeting price support.

#
1	BEAM	Beam Therapeutics Inc. Common Stock	79.4	31.82%	13.69	-2.89%	critical
2	ABSI	Absci Corporation Common Stock	78.4	30.03%	9.06	+0.24%	critical
3	WGS	GeneDx Holdings Corp. Class A Common Stock	76.1	34.88%	7.27	-23.55%	critical
4	NTLA	Intellia Therapeutics, Inc	75.6	38.56%	11.05	-14.39%	critical
5	CRSP	CRISPR Therapeutics AG	75.5	22.37%	13.09	-15.52%	critical
6	GENB	Generate Biomedicines, Inc. Common Stock	72.8	15.69%	8.87	-3.67%	high
7	ARCT	Arcturus Therapeutics Holdings Inc. Common Stock	71.2	23.75%	7.37	-24.00%	high
8	PRME	Prime Medicine, Inc. Common Stock	70.7	30.47%	4.80	+36.86%	high
9	SCTX	Scribe Therapeutics Inc. Common Stock	68.9	21.79%	4.01	-21.31%	high
10	RXRX	Recursion Pharmaceuticals, Inc. Class A Common Stock	67.5	32.93%	6.10	-12.74%	high
11	BFLY	Butterfly Network, Inc.	64.7	18.28%	7.11	-18.93%	high
12	KYMR	Kymera Therapeutics, Inc. Common Stock	64.2	12.52%	10.49	+19.50%	high

Market cap, valuation, and short-interest metrics are joined to the latest ARKG holdings snapshot; each ticker links to its full quote and analysis page.